These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 16013035)
41. Cytotoxic activity of Brazilian Cerrado plants used in traditional medicine against cancer cell lines. de Mesquita ML; de Paula JE; Pessoa C; de Moraes MO; Costa-Lotufo LV; Grougnet R; Michel S; Tillequin F; Espindola LS J Ethnopharmacol; 2009 Jun; 123(3):439-45. PubMed ID: 19501276 [TBL] [Abstract][Full Text] [Related]
42. Anticancer mechanisms of YC-1 in human lung cancer cell line, NCI-H226. Chen CJ; Hsu MH; Huang LJ; Yamori T; Chung JG; Lee FY; Teng CM; Kuo SC Biochem Pharmacol; 2008 Jan; 75(2):360-8. PubMed ID: 17880926 [TBL] [Abstract][Full Text] [Related]
43. Pharmacological and toxicological evaluation of a new series of thymidylate synthase inhibitors as anticancer agents. Benassi L; Magnoni C; Giudice S; Bertazzoni G; Costi MP; Rinaldi M; Venturelli A; Coppi A; Rossi T Anticancer Res; 2006; 26(5A):3499-504. PubMed ID: 17094473 [TBL] [Abstract][Full Text] [Related]
44. Pyrazoline bearing benzimidazoles: search for anticancer agent. Shaharyar M; Abdullah MM; Bakht MA; Majeed J Eur J Med Chem; 2010 Jan; 45(1):114-9. PubMed ID: 19883957 [TBL] [Abstract][Full Text] [Related]
48. A sensitive assay for the evaluation of cytotoxicity and its pharmacologic modulation in human solid tumor-derived cell lines exposed to cancer-therapeutic agents. Mirzayans R; Andrais B; Scott A; Tessier A; Murray D J Pharm Pharm Sci; 2007; 10(2):298s-311s. PubMed ID: 17718933 [TBL] [Abstract][Full Text] [Related]
49. A structural analysis of the differential cytotoxicity of chemicals in the NCI-60 cancer cell lines. Chakravarti SK; Klopman G Bioorg Med Chem; 2008 Apr; 16(7):4052-63. PubMed ID: 18243714 [TBL] [Abstract][Full Text] [Related]
50. The hollow fibre model in cancer drug screening: the NCI experience. Decker S; Hollingshead M; Bonomi CA; Carter JP; Sausville EA Eur J Cancer; 2004 Apr; 40(6):821-6. PubMed ID: 15120037 [TBL] [Abstract][Full Text] [Related]
51. Characterization of chemosensitivity and resistance of human cancer cell lines to platinum(II) versus platinum(IV) anticancer agents. Hamberger J; Liebeke M; Kaiser M; Bracht K; Olszewski U; Zeillinger R; Hamilton G; Braun D; Bednarski PJ Anticancer Drugs; 2009 Aug; 20(7):559-72. PubMed ID: 19491657 [TBL] [Abstract][Full Text] [Related]
52. Functionalised cyclopentadienyl zirconium compounds as potential anticancer drugs. Allen OR; Knox RJ; McGowan PC Dalton Trans; 2008 Oct; (39):5293-5. PubMed ID: 18827935 [TBL] [Abstract][Full Text] [Related]
53. A quantitative method for measuring the antitumor potency of recombinant human endostatin in vivo. Xu YF; Zhu LP; Hu B; Rong ZG; Zhu HW; Xu JM; Wu ZW; Wang JJ; Xu GX Eur J Pharmacol; 2007 Jun; 564(1-3):1-6. PubMed ID: 17346697 [TBL] [Abstract][Full Text] [Related]
54. Update on NCI in vitro drug screen utilities. Holbeck SL Eur J Cancer; 2004 Apr; 40(6):785-93. PubMed ID: 15120034 [TBL] [Abstract][Full Text] [Related]
55. C5-Modified nucleosides exhibiting anticancer activity. Lee YS; Park SM; Kim HM; Park SK; Lee K; Lee CW; Kim BH Bioorg Med Chem Lett; 2009 Aug; 19(16):4688-91. PubMed ID: 19596579 [TBL] [Abstract][Full Text] [Related]
56. Substituted E-3-(2-chloro-3-indolylmethylene)1,3-dihydroindol-2-ones with antitumor activity. Effect on the cell cycle and apoptosis. Andreani A; Burnelli S; Granaiola M; Leoni A; Locatelli A; Morigi R; Rambaldi M; Varoli L; Calonghi N; Cappadone C; Farruggia G; Zini M; Stefanelli C; Masotti L J Med Chem; 2007 Jul; 50(14):3167-72. PubMed ID: 17559205 [TBL] [Abstract][Full Text] [Related]
57. Nonlinear model predictive control for dosing daily anticancer agents using a novel saturating-rate cell-cycle model. Florian JA; Eiseman JL; Parker RS Comput Biol Med; 2008 Mar; 38(3):339-47. PubMed ID: 18222419 [TBL] [Abstract][Full Text] [Related]